C-erbB-2过度表达对肺腺癌化疗疗效影响的临床观察

The Clinical Observation About Over Expressions of C-erbB-2 on Prognosis of Lung Adenocarcinoma

目的前瞻性探讨C-erbB-2表达对肺腺癌化疗疗效及生存期的影响。方法本组85例肺腺癌,给予盖诺30 mg/m2,d1、8+顺铂40 mg×3 d方案化疗,每例不少于2个疗程,85例病理标本采用免疫组化法进行C-erbB-2表达检测,并长期随访。结果C-erbB-2过度表达患者化疗疗效及2年生存率均低于C-erbB-2未表达者(P<0.05)。结论C-erbB-2过度表达的肺腺癌患者肿瘤容易复发,化疗疗效差,且生存期短,与C-erbB-2表达阴性的患者之间有明显差异。

Objective To explore prospectively the expressions of C-erbB-2 on the chemothreapy and survival in lung adenocarcinoma patients. Methods NVB 30 mg/m^2 , d1.8 and DDP 40 mg × 3 d were used in 85 lung adenocarcinoma patients. Each case was treated at least 2 times of therapy, The expression of C-erbB-2 in histopathologic slides of all 85 lung adenocarcinoma cases were investigated with immunohistochemical method. Results The chem-therapeutic effect and 2-year survival of patients who have overexpressions of C-erbB-2 were lower than that who have negative expression of C-erbB-2. Conclusions Compared with patients who have negative expression of C-erbB-2, patients who have overexpressions of C-erbB-2 were easily to recur, have lower chem-therapeutic effect and lower survival rate. It has significant difference .